Biological Basis for Chemoprevention of Ovarian Cancer. Addendum
Abstract
To better understanding the etiology of ovarian cancer, we have initiated a case-control study that considers genetic susceptibility, epidemiologic factors and somatic alterations. Subjects are interviewed in their homes and 1,100 cases and 1,000 controls have been accrued. Blood and cancer samples have been collected and molecular analyses of genetic polymorphisms have been performed. We have performed an Illumina array experiment with 1,536 haplotype tagging single nucleotide polymorphisms in about 150 candidate genes with an emphasis on DNA repair genes and found preliminary evidence of an association of this pathway with ovarian cancer risk. We also have played a leadership role in establishing an international consortium of groups to validate initial associations. A chemoprevention trial with levoneorestrel in chickens demonstrated a protective effect and we have shown that progestin mediated apoptosis in the ovarian epithelium is mediated by transforming growth factor-beta. In vitro data has suggested that vitamin D analogues may also represent appealing chemopreventives. A chemoprevention trial in chickens that incorporates both progestins and vitamin D analogues has been performed. These studies have the potential to increase our ability to identify high-risk women and to lead to the development of chemoprevention strategies that might decrease mortality from this disease.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2007
- Accession Number
- ADA477276
Entities
People
- Andrew Berchuck
Organizations
- Duke University Hospital